Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study on tolerant rats, maternal and developmental toxicity from levo-alpha-acetyhnethadol hydrochloride were observed at all doses, without specific fetal toxicity or teratogenic effects.

In this study, EPC-K, a compound with antioxidant and moisturizing effects, was found to decompose significantly under certain conditions, impacting its stability in quasi drug hair-growing products.

This theoretical study suggests that certain cannabinoid derivatives could potentially be effective as androgen receptor and 5α-reductase enzyme inhibitors, indicating they may be promising candidates for prostate cancer treatment based on their higher affinity to target proteins compared to standard drugs.

This study reports that using molecular docking methods, beta-sitosterol and stigmasterol from Serenoa repens were identified as potential natural inhibitors of the 5AR1 enzyme, which could serve as novel treatments for androgenetic alopecia based on their inhibitory action observed in a laboratory setting.

This study suggests that finasteride may inhibit the enzyme PNMT, potentially contributing to its sexual and psychological side effects.

This meta-analysis concluded that 5α-reductase inhibitors may increase the risk of mild depression, particularly with dutasteride, in patients treated for benign prostatic hyperplasia and androgenic alopecia.

This study found that Medicare patients with benign prostatic hyperplasia had high adherence to 5-alpha reductase inhibitor therapy, which was associated with a reduced risk of needing surgical intervention.

This study found that Finnish men using 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had improved disease-specific survival compared to non-users, suggesting potential benefits of the treatment.

In this study, the SRD5A2 rs523349 polymorphism was significantly associated with an increased risk of miscarriage, particularly during the second trimester.

In a cell-free test setting, this study found that a novel saw palmetto extract effectively inhibited the 5α-reductase type II enzyme, showing promising bioactivity comparable to finasteride for promoting prostate health.

This study explored the optimization of phytochemicals from Alstonia boonei to develop potential 5-alpha reductase inhibitors for Benign Prostatic Hyperplasia, finding promising analogs with enhanced binding affinity and stability compared to Finasteride, warranting further experimental validation.

In a rat model of benign prostatic hyperplasia, this study found that purple corn extract may improve symptoms by inhibiting prostate enlargement, reducing androgen receptor signaling, and exerting anti-inflammatory effects.

This review of legal cases found that 5α-reductase inhibitors, alleged to cause sexual, mental, and physical side effects, have led to numerous lawsuits with increasing litigation expected in the future.

This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.

This study found that among men with Benign Prostatic Hyperplasia, treatment with the 5α-reductase inhibitor finasteride for three months significantly reduced levels of dihydrotestosterone and estradiol, hormones involved in prostate enlargement, without altering follicle-stimulating hormone or luteinizing hormone levels.

This study on rats found that finasteride and dutasteride increased collagen density in penile tissues and caused changes in prostate cells, but did not significantly alter erectile pressures compared to controls.

This study designed a novel model for 5a-reductase enzyme inhibitors using pharmacophore and 3D QSAR techniques, potentially allowing for improved prediction and development of drug therapies targeting benign prostatic hyperplasia.

This review discusses the clinical applications and adverse effects of 5-alpha reductase inhibitors for treating benign prostatic hyperplasia and androgenic alopecia, noting controversies around their implications for other diseases, without reporting new results.

This article discusses adverse immune-mediated skin reactions associated with TNF-alpha inhibitors, highlighting paradoxical reactions such as psoriasis that occur despite being treated with medications intended to alleviate the condition.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

This study found that from 2011 to 2015, a substantial portion of women in the Netherlands dispensed finasteride or dutasteride were not using adequate contraception, prompting calls for improved risk management.

This study suggests that 5-alpha-reductase inhibitors may reduce the rate of clinical progression in men with low-risk prostate cancer who choose active surveillance.

In this study, researchers found a statistically significant increase in reports of suicidality and depression associated with finasteride use, especially in younger individuals, whereas dutasteride showed no significant signal for suicidality and a weaker signal for depression.

In this study, fenugreek seed extract showed significant androgenic and spermatogenic effects in male rats, likely through inhibiting testosterone metabolism, without impacting cardiovascular health.

This study investigates the potential of onion extract as a treatment for androgenetic alopecia by using in silico and ADME/T analyses to examine how active compounds from onions interact with the 5-alpha-reductase enzyme.

This study explored a new dutasteride nanocarrier for alopecia therapy, concluding that ingredient concentration is key to achieving the optimal particle size, stability, and skin permeation for extended drug release.

This commentary discusses how recent shifts in prostate cancer screening and management may render 5-alpha reductase inhibitors irrelevant for chemoprevention, despite evidence of their long-term safety and effectiveness in preventing low-grade prostate cancer.

This case report describes a 36-year-old Pakistani phenotypic female diagnosed with 46,XY 5-alpha-reductase deficiency, highlighting that such disorders of sexual development can manifest with symptoms like obesity, hirsutism, and amenorrhea later in life due to unique circumstances.

This study suggests that type I 5-alpha reductase may also play a role in hair growth, with dutasteride potentially being more potent than finasteride in modulating key hair growth gene expressions.